- Continuous focusing of service activity on biotechnological preclinical studies in ophthalmology
- Identification of the strategic axes of clinical development in ophthalmology in progress
- Cash of EUR 3.8 million (excluding CIR) as of September 30, 2022
TOULOUSE, France & LAKELAND, Mich.–(BUSINESS WIRE)–Regulatory News:
ABIONYX Pharma, (FR0012616852 – ABNX – Eligible PEA PME) (Paris:ABNX), a next-generation biotech company dedicated to the discovery and development of innovative therapies, announces its cash position for 3th Quarter ended September 30, 2022 and provides an overview of the highlights of the period.
The company achieved consolidated sales of €3,789,000 in the first nine months of the year, adjusted for intra-group transactions. IRIS Pharma reported sales of €4,196,000 in the first nine months of 2022. Regarding the activities dedicated to the discovery and development of innovative therapies aimed at improving the lives of patients, ABIONYX Pharma did not generate any revenues in this quarter and in the first nine months of the financial year.
The consolidated sales reflect the fact that since the integration of IRIS Pharma, the biotech company has decided to focus its efforts on preclinical studies of Bio-HDL in ophthalmology, in order to improve the strategic development axes for entering the clinical phase to be determined as soon as possible. As previously announced, the company will shortly communicate its strategy in ophthalmology.
Regarding the kidney right, the last patient in the phase 2a clinical trial for CER-001 called RACERS was enrolled on October 4th in collaboration with the University of Bari with sepsis and high risk of developing acute kidney injury. Last April, ABIONYX Pharma announced positive interim results in this clinical study, showing rapid reversal of the cytokine cascade in septic patients and rapid improvement in inflammatory biomarkers, including leukocytosis, compared to standard of care.
In addition, the company continues to receive new requests for Compassionate Access Authorization (AAC) for Bio-HDL (CER-001) from several hospitals in France and around the world.
As of September 30, 2022, ABIONYX Pharma’s cash position prior to receipt of the CIR was EUR 3.8 million. The Company recalls that Phase 2a is fully funded and that no dilutive financial instrument has been employed.
Given the progress made in collecting and processing data to date, the final results of the RACERS study will be announced in early January 2023.
About ABIONYX Pharma
ABIONYX Pharma is a next-generation biotech company that intends to contribute to health through innovative therapies in indications with no effective or existing treatment, even the rarest. Thanks to its research partners, physicians, biomedical manufacturers and shareholders, the company innovates daily to offer drugs to treat kidney and eye diseases or new HDL vectors for targeted drug delivery.
Louis Victor Delouvrier
+33 (0)1 44 71 98 53
+33 (0)1 44 71 94 98